Myopia Market

Key Highlights 

• Market size of Pharmaceutical therapies for Myopia was found to be USD XX Million in 7MM, while the non-pharmacological therapy based Market was USD XX million.
• Among 7MM countries, the United States accounts for the XX% of the overall market size of Myopia in 2019.
• Among the EU-5 countries, France accounts for highest market size for Myopia followed by Germany, UK, Italy and Spain. 

Key Factors Driving the Myopia Market

Myopia burden fueling Myopia market expansion

Myopia prevalence has escalated into a public health challenge, particularly in East Asia, where urban prevalence exceeds 70–80% in adolescents. Based on secondary analysis, a 66% rise in the prevalence of myopia was observed in the United States over a 30-year period ending in 2004. Continued growth is projected through 2034, driven by increased near-work activities and reduced outdoor exposure among younger populations.

Myopia treatment paradigm

Current myopia treatments, including eyeglasses, contact lenses, and refractive surgeries like LASIK, effectively correct blurry distance vision. Emerging interventions such as low-dose atropine eye drops, orthokeratology (Ortho-K), and specialized lenses like ZEISS MyoVision and Paragon CRT aim to slow progression, particularly in children, though each has limitations in terms of side effects, cost, or compliance. The myopia treatment market is growing across the 7MM, driven by rising prevalence, technological advancements, and increased demand for minimally invasive options, but the absence of a permanent cure and varied treatment efficacy remain key challenges.

Myopia Competitive Landscape

The pipeline of emerging treatments for myopia shows strong potential, with several mid-to-late-stage candidates currently under evaluation in myopia clinical trials. Prominent examples include EssilorLuxottica's Stellest™ lenses, Cloudbreak Pharma’s CBT-009, Sydnexis’ SYD-101, and the Kubota wearable device for myopia control. 

Additionally, microdose atropine delivery systems (e.g., Eyenovia) and novel optical interventions from companies like CooperVision and Bausch + Lomb are gaining traction. Early-stage research is also exploring gene therapy for pathological myopia, highlighting a shift toward disease-modifying strategies aimed at slowing axial elongation and revolutionizing the future treatment landscape.

Myopia market dynamics and opportunity

As preventive treatment becomes a focus, the pediatric population represents the most commercially attractive segment. High prevalence and recurring treatment requirements position myopia as a multi-billion-dollar opportunity by 2034.

DelveInsight's "Myopia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Myopia, historical and forecasted epidemiology as well as the Myopia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Myopia market report provides current treatment practices, emerging drugs, Myopia market share of the individual therapies, current and forecasted Myopia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Myopia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Myopia market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Myopia Overview 

Myopia, or nearsightedness, is indeed a common refractive error where distant objects appear blurry due to the focal point falling in front of the retina, rather than directly on it. Your explanation highlights how myopia is a growing concern globally, leading to significant public health challenges.

Age and genetics are key factors contributing to myopia, and visual stress from activities that require prolonged close-up focus, like reading or using digital devices, can exacerbate its development and progression. 

Myopia Disease Understanding and Treatment Algorithm

The DelveInsight’s Myopia market report gives a thorough understanding of the Myopia treatment  by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Myopia Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Myopia.

Myopia Treatment

It covers the details of conventional and current medical therapies available in the Myopia market for the treatment of the condition. It also provides Myopia treatment algorithms and guidelines in the United States, Europe, and Japan.

Myopia Epidemiology 

The Myopia epidemiology section provides insights about the historical and current Myopia patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Myopia market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Epidemiological segmentation fot Myopia market includes Total Prevelant Cases, Severity Specific Prevelant Cases, Age Specific Prevelant Cases, Diagnosed and treated cases of Myopia.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Myopia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Myopia Epidemiology

The epidemiology segment also provides the Myopia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Myopia Recent Developments

• In March 2025, Sydnexis, Inc. announced that the FDA has accepted its New Drug Application (NDA) for SYD-101, with a PDUFA target action date of October 23, 2025. If approved, SYD-101 would be the first pharmaceutical treatment for pediatric myopia progression in the U.S.
• In January 2025, ZEISS Medical Technology announced that the MEL® 90 received FDA approval for myopia, hyperopia, and mixed astigmatism. The excimer laser integrates into the Corneal Refractive Workflow, providing U.S. surgeons with a fast, reliable, and streamlined surgery experience, complementing the VISUMAX® 800 with SMILE® pro to enhance refractive practices and improve patient outcomes.

Myopia Drug Chapters

The drug chapter segment of the Myopia report encloses the detailed analysis of Myopia market drugs and late-stage (Phase-III and Phase-II) Myopia pipeline drugs. It also helps to understand the Myopia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Myopia Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Myopia treatment.

Myopia Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Myopia treatment.

Myopia Market Outlook

The Myopia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Myopia market trends by analyzing the impact of current Myopia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Myopia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Myopia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Myopia market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Myopia market in 7MM.

The United States Market Outlook

This section provides the total Myopia market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Myopia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Myopia market size and market size by therapies in Japan is also mentioned.

Myopia Drugs Uptake

This section focuses on the rate of uptake of the potential Myopia drugs recently launched in the Myopia market or expected to get launched in the market during the study period 2019-2032. The analysis covers Myopia market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Myopia Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Myopia market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Myopia Pipeline Development Activities

The Myopia report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Myopia key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Myopia report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Myopia emerging therapies.

Reimbursement Scenario in Myopia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Myopia market trends, we take KOLs and SMEs ' opinion working in the Myopia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Myopia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Myopia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Myopia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Myopia epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Myopia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Myopia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Myopia market

Report Highlights

• In the coming years, the Myopia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Myopia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Myopia. The launch of emerging therapies will significantly impact the Myopia market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Myopia
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Myopia Report Insights

• Myopia Patient Population
• Therapeutic Approaches
• Myopia Pipeline Analysis
• Myopia Market Size and Trends
• Myopia Market Opportunities
• Impact of upcoming Myopia Therapies

Myopia Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Myopia Epidemiology Segmentation
• Myopia Key Cross Competition
• Myopia Highly Analyzed Market
• Myopia Drugs Uptake

Myopia Report Assessment

• Current Treatment Practices
• Unmet Needs
• Myopia Pipeline Product Profiles
• Myopia Market Attractiveness
• Myopia Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Myopia drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Myopia total market size as well as market size by therapies across the 7MM during the forecast period (2023-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Myopia market size during the forecast period (2023-2032)?
• At what CAGR, the Myopia market is expected to grow by 7MM during the forecast period (2023-2032)?
• What would be the Myopia market outlook across the 7MM during the forecast period (2023-2032)?
• What would be the Myopia market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Myopia?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Myopia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Myopia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Myopia?
• Out of all 7MM countries, which country would have the highest prevalent population of Myopia during the forecast period (2023-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2023-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Myopia treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Myopia in the USA, Europe, and Japan?
• What are the Myopia marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Myopia?
• How many therapies are in-development by each company for Myopia treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Myopia treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Myopia therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the ongoing Myopia clinical studies  and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Myopia?
• What are the global historical and forecasted market of Myopia?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Myopia market
• To understand the future market competition in the Myopia market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Myopia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Myopia market
• To understand the future market competition in the Myopia market